Verve Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Verve Therapeutics (VERV), a clinical-stage company focused on genetic medicines for cardiovascular disease, has announced its participation in two major investor conferences in June 2025. The company's management will engage in fireside chats at the Jefferies Global Healthcare Conference on June 4 at 9:20 a.m. ET in New York, and the Goldman Sachs 46th Annual Global Healthcare Conference on June 9 at 11:20 a.m. ET in Miami. Both events will be available via webcast on the company's website and archived for 30 days.

BOSTON , May 28, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that management will participate in fireside chats during the following investor conferences:

• Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 9:20 a.m. ET in New York, NY
• Goldman Sachs 46^th Annual Global Healthcare Conference on Monday, June 9, 2025, at 11:20 a.m. ET in Miami, FL

Live webcasts will be available in the investor section of the company's website at www.vervetx.com. The webcasts will be archived for 30 days following the fireside chats.

About Verve Therapeutics 
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The company’s lead programs –VERVE-102, VERVE-201, and VERVE-301 – target the three cholesterol drivers of atherosclerosis: low-density lipoprotein cholesterol (LDL-C), triglycerides (TRLs), and lipoprotein (a) [Lp(a)]. VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia (HoFH). VERVE-301 is designed to permanently turn off the LPA gene to reduce Lp(a) levels. Lp(a) is a genetically validated, independent risk factor for ASCVD, ischemic stroke, thrombosis, and aortic stenosis. For more information, please visit www.VerveTx.com.

Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com

Media Contact
Ashlea Kosikowski
1AB
ashlea@1abmedia.com

FAQ

When is Verve Therapeutics (VERV) presenting at the Jefferies Global Healthcare Conference 2025?

Verve Therapeutics will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 9:20 a.m. ET in New York, NY.

Where can I watch Verve Therapeutics' (VERV) investor conference presentations?

The webcasts will be available in the investor section of Verve Therapeutics' website at www.vervetx.com and will be archived for 30 days after the presentations.

What conferences is Verve Therapeutics (VERV) attending in June 2025?

Verve Therapeutics is participating in the Jefferies Global Healthcare Conference on June 4 and the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025.

What time is Verve Therapeutics' (VERV) presentation at the Goldman Sachs Healthcare Conference?

Verve Therapeutics will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025, at 11:20 a.m. ET in Miami, FL.